Overview

A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

Status:
Completed

Trial end date:
2019-07-03

Target enrollment:

Participant gender:

Summary

Despite substantial improvements of patients outcome in advanced RCC, durable and complete response is uncommon. The majority of patients eventually develop resistance and exhibit disease progression. Combining a PD-1 inhibitor, which has shown single-agent efficacy with axitinib may provide additional clinical benefit compared to axitinib alone.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Axitinib
Pembrolizumab